CTOs on the Move


 
MiMedx is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.mimedx.com
  • 1775 West Oak Commons CT. NorthEast
    Marietta, GA USA 30062
  • Phone: 770.651.9100

Executives

Name Title Contact Details

Similar Companies

St. Marys Children's Hospital

St. Marys Children's Hospital is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

onramp 113

onramp 113 is a Dixon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harbor Biosciences

Harbor Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tgs Technologies

Tgs Technologies, Llc is a Cranberry Twp, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.